Published on: Friday, 03 January 2025 ● 3 Min Read
NEW YORK--(BUSINESS WIRE)--KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends observed in the December 2024 servicer reporting period. The delinquency rate among KBRA-rated U.S. private label CMBS in December increased to 6.5%, up 55 basis points (bps) from November. The total delinquent plus current but specially serviced loan rate (collectively, the distress rate) also increased by a slightly lower 38 bps to 9.33%. With another month of increases in hand, the 2024 delinquency and distress rates ended the year meaningfully up from 4.21% and 6.65% at year-end 2023, respectively.
Notably, while most sectors experienced an increase in their delinquency and distress rates over the past year, office and multifamily saw the biggest increases. Office delinquencies more than doubled year-over-year to 10.76% from 4.83%, while its distress rate approached 15%, versus last year’s 8.55%. The multifamily distress rate also more than doubled, to 9.61% from 4.02%, although much of the increase was driven by the special servicing transfer of a few large loans.
In December, CMBS loans totaling $2.5 billion were newly added to the distress rate, of which 51.7% ($1.3 billion) were due to imminent or actual maturity default. The office sector experienced the highest volume of newly distressed loans (37%, $939 million), followed by multifamily (32.6%, $826.3 million), retail (12.8%, $325.6 million), and mixed-use (7%, $176.4 million).
Key observations of the December 2024 performance data are as follows:
In this report, KBRA provides observations across our $332.3 billion rated universe of U.S. private label CMBS including conduits, single-asset single borrower (SASB), and large loan (LL) transactions.
Click here to view the report.
Related Publications
About KBRA
KBRA is a full-service credit rating agency registered in the U.S., the EU, and the UK, and is designated to provide structured finance ratings in Canada. KBRA’s ratings can be used by investors for regulatory capital purposes in multiple jurisdictions.
Doc ID: 1007435
No comments posted
© 2019 KIVAA Group | All right reserved. www.bankingontechnology.com
Leave a reply: